Antibody drugs that degrade disease-causing autoantibodies
Raised to date
$55M
of $73.3M offered across 1 Form D filing
Kaigene develops antibody therapeutics for autoimmune diseases driven by pathogenic antibodies. Its PDEG (Pathogenic Antibody Degrader) platform is designed to selectively degrade harmful autoantibodies and suppress the B cells that produce them. It licensed its nonclinical assets KG006, an FcRn inhibitor, and KG002 to Celltrion in November 2025 for $8 million upfront and up to $736 million in milestones, and licensed KG006 in Japan to Taisho Pharmaceutical in July 2026.
Dual-acting PDEG antibodies that both clear disease-specific autoantibodies and suppress the B cells producing them, plus a NanoBx nanobody brain shuttle for CNS autoimmune disease.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Oct 14, 2026 | Equity | $55M/ $73.3M | Form D |
Therapeutic antibody platform
Pathogenic Antibody Degrader platform for antibodies that selectively degrade disease-causing autoantibodies and suppress autoantibody-producing B cells.
Built for
Patients with antibody-driven autoimmune diseases, reached through pharma licensing partners
